• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Korea·Healthcare·007570.KS
Share

Ilyang Pharmaceutical Co.,Ltd Stocks

₩ 8340Last Updated 05.08.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

₩ 103.65M

₩ 8340
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Headquartered in Yongin, South Korea, Ilyang Pharmaceutical Co.,Ltd is a prominent pharmaceutical enterprise that has been operating since its establishment in 1946. The company, which was formerly known as Il-Yang Pharm. Ind. Co. until its renaming in May 1991, primarily conducts its business in South Korea. It develops and provides a comprehensive portfolio of medicines addressing various therapeutic areas, such as oncology, cardiovascular health, endocrine and metabolic conditions, women's health (including female hormone treatments and cheonjiyang), urology, ophthalmology, liver diseases, pain and inflammation, digestive system issues, dermatological complaints, and respiratory illnesses. Their pharmaceutical offerings also extend to nutrient infusions, neurological medications, antibiotics, antifungals, insecticides, and vaccines. In addition to medicinal products, Ilyang manufactures a range of consumer health items, including health drinks, dietary supplements, health foods, cosmetics, and other beverages. The company is also a producer of numerous pharmaceutical raw materials, specifically various aluminum and magnesium compounds. Ilyang Pharmaceutical has an international footprint, exporting its diverse product range to roughly 14 countries worldwide.

Company Valuation

Undervalued
6/7

Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. In particular, the stock is underpriced on P/E, of fair value on

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

05.08.2026 19:06

After a brief pause, the European stock market has returned to record highs: Who are the leaders, and who are the laggards?

05.08.2026 18:35

SpaceX shares plummeted 12% at the opening bell. Do analysts share this pessimism?

05.08.2026 18:12

Lucid's stock plummeted amid a restructuring and delays in the launch of its budget model

05.08.2026 17:50

Samsung has unveiled new memory technologies for AI. It is competing for a $1 trillion market.

05.08.2026 17:28

Kazakhstan Plans New $500 Million Panda Bond Offering — Bloomberg

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026